Systematic Evaluation of Tumoral 99mTc-MAA Uptake Using SPECT and SPECT/CT in 502 Patients Before 90Y Radioembolization

The aim of this study was to evaluate the Tc-99m-macroaggregated albumin (Tc-99m-MAA) uptake of primary and secondary liver tumors in a large patient cohort before Y-90 radioembolization. Methods: We included 502 patients during the years 2005-2013 (55% male; mean age, 62 +/- 11 y), who were examined with Tc-99m-MAA SPECT or SPECT/CT before planned radioembolization. The patients had colorectal cancer (CRC; n = 195, 38.8%), neuroendocrine tumors (NET; n = 77, 15.3%), mammary cancer (MAM; n = 68, 13.5%), hepatocellular carcinoma (HCC; n = 59, 11.8%), cholangiocellular carcinoma (CCC; n = 40, 8.0%), or urologic tumors (URO; n = 14, 2.8%). SPECT with coregistered contrast-enhanced CT or MR imaging and SPECT/CT images of these patients were analyzed using dedicated software with regard to the Tc-99m-MAA uptake of the liver tumors. Regions of interest were drawn around the lesions manually and quantified the uptake of up to 3 lesions per patient and also adjacent healthy liver tissue without evidence of tumor. We quantified maximum and mean counts per pixel and calculated tumor-to-background ratio (TBR). Data are reported as mean +/- SD. Lesion uptake was classified as being homogeneously high (grade 1), heterogeneously high (grade 2), equal to that of the liver (grade 3), or low (grade 4). Results: Grade 1 uptake was seen in 230 of 1,008 lesions (with the highest rates in sarcoma [47%], MAM [37%], and NET [32%]), grade 2 in 706 lesions (with the highest rates in CRC [77%], HCC [75%], and CCC [74%]), grade 4 in 57 lesions (with the highest rates in pancreatic cancer [17%], sarcoma [SAR] [13%], and MAM [8%]), and grade 3 in only 15 lesions. In quantitative analysis, the mean TBRmax of all lesions was 4.8 +/- 4.1 (range, 0.2-50.1), with the highest values in HCC (6.0 +/- 4.7; range, 1.4-21.6), NET (5.4 +/- 4.9; range, 0.8-43.0), pancreatic cancer (4.0 +/- 2.8; range, 0.9-12.2), and CCC (4.7 +/- 2.9; range, 0.9-11.6), and the lowest values in SAR (3.5 +/- 1.8; range, 0.8-2.7) and MAM (3.6 +/- 2.2; range, 0.9-11.6). The mean TBRmean was 1.9 +/- 1.0 (range, 0.1-7.2), with the highest values in NET (2.2 +/- 1.2; range, 0.2-7.2), HCC (2.1 +/- 1.2; range, 0.3-6.3), and CCC (2.0 +/- 1.0; range, 0.2-6.3) and the lowest values in MAM (1.7 +/- 0.8; range, 0.2-4.1), CRC (1.8 +/- 0.9; range, 0.4-6.6), and SAR (1.7 +/- 1.1; range, 0.3-3.9). Conclusion: The Tc-99m-MAA uptake of different tumor entities shows a wide variation, with generally highest values for NET, HCC, and CCC and lowest values for MAM, CRC, and SAR. However, the variation of uptake within the different tumor entities is high.